Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Segmental Overgrowth Syndrome
DRKS00010085Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in segmental overgrowth syndrome, Other phakomatoses, Other specified congenital malformation syndromes and 1 more, sponsored by Universitätsklinikum Freiburg. Started Nov 2016; status: completed.
02
Drugs
sirolimus
03
Conditions
segmental overgrowth syndromeOther phakomatosesOther specified congenital malformation syndromesCongenital Overgrowth Syndrome
Beyond the preview
Go deeper on DRKS00010085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010085.